Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Sold by Axa S.A.

AXA S.A. trimmed its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 14.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 293,755 shares of the company's stock after selling 51,128 shares during the quarter. AXA S.A. owned about 0.20% of Denali Therapeutics worth $5,987,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Sterling Capital Management LLC lifted its position in Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after acquiring an additional 885 shares during the period. KBC Group NV boosted its position in shares of Denali Therapeutics by 75.8% during the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares during the last quarter. AlphaQuest LLC increased its position in Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after purchasing an additional 4,449 shares during the last quarter. Finally, E Fund Management Co. Ltd. increased its position in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock worth $204,000 after purchasing an additional 2,436 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on DNLI shares. Wedbush decreased their target price on shares of Denali Therapeutics from $32.00 to $30.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Robert W. Baird reduced their target price on Denali Therapeutics from $30.00 to $29.00 and set an "outperform" rating on the stock in a research report on Thursday. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a report on Tuesday, February 11th. They set a "buy" rating and a $31.00 price target for the company. Finally, William Blair upgraded shares of Denali Therapeutics to a "strong-buy" rating in a report on Thursday, April 24th. One research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Stock Up 4.0%

Denali Therapeutics stock traded up $0.58 during mid-day trading on Monday, reaching $14.95. 219,706 shares of the company's stock were exchanged, compared to its average volume of 1,088,830. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The company has a market cap of $2.17 billion, a P/E ratio of -5.42 and a beta of 1.49. The company has a fifty day moving average of $14.27 and a 200-day moving average of $19.99.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same quarter last year, the business posted ($0.68) earnings per share. Equities research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.